Overview

NP001, Alzheimer's Disease, and Blood Markers of Inflammation

Status:
Terminated
Trial end date:
2018-07-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1 placebo-controlled biomarker study of NP001 in individuals with Alzheimer's Disease.
Phase:
Phase 1
Details
Lead Sponsor:
Beau Nakamoto
Collaborator:
Neuraltus Pharmaceuticals, Inc.